Tumor hypoxia is associated with radioresistance, chemoresistance, and metastasis, which eventually lead to cancer progression and a poor patient prognosis. RON [also known as macrophagestimulating protein receptor (MST1R)] belongs to the c-MET [also known as hepatocyte growth factor receptor (HGFR)] receptor tyrosine kinase (RTK) superfamily. To identify the interaction partners of RON nuclear translocation in response to hypoxia, the nuclear extract of TSGH8301 bladder cancer cells was immunoprecipitated for tandem mass profiling analysis. Nuclear RON interacted with adenosine triphosphate (ATP)-dependent DNA helicase 2 (Ku70) and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) to activate nonhomologous end joining (NHEJ) DNA repair. The interaction was time dependent, extending 3 to 24 hours posthypoxia or until the components had been exposed to the chemotherapeutic drugs doxorubicin and epirubicin. Stable knockdown experiments in vitro suggest the importance of RON for the chemoresistance of cancer cells under hypoxia. In addition, the tyrosine kinase domain of nuclear RON is crucial for interaction with Ku70 under hypoxia. J82 cells transfected with RON showed a survival advantage in the presence of epirubicin and hypoxia. This suggests that nuclear RON activates NHEJ repair by interacting with Ku70/DNA-PKcs and inhibiting RON activity to increase cancer cell chemosensitivity.
Introduction
Most solid tumors contain regions of hypoxia or anoxia that indicate a negative clinical prognosis for cancer patients because of local resistance and systemic metastases (1) . A majority of studies on hypoxia-induced signaling responses have focused on the role of transcription factor hypoxia-inducible factor (HIF)-1a (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db¼ gene&cmd¼Retrieve&dopt¼full_report&list_uids¼3091HIF-1a) and angiogenesis (2) . Several explanations have been proposed to account for the negative effect of hypoxia on prognosis, including the ability of hypoxia to drive genomic instability and change DNA damage repair pathways (3) . It is well known that maintaining genomic DNA integrity is critical for cell survival in all eukaryotic organisms, and that DNA doublestrand breaks (DSB) are the common genotoxic type of DNA lesion (4, 5) . DSBs can be repaired by nonhomologous end joining (NHEJ) or homologous recombination (HR), in which NHEJ repair is faster and more versatile and adaptable to imperfect ends compared with HR (6, 7) . Defects in these repair pathways cause genomic instability and increased tumorigenicity (7) . Because of the potential of hypoxia-mediated changes in transcription and translation, clarifying the efficacy of anticancer drugs under hypoxic stress is required (3) .
NHEJ is more dominant than HR as a DNA repair pathway of mammalian cells (8) . This pathway directly rejoins the broken ends of DNA without using a homologous sequence as the repair template, in contrast to HR repair, which uses sister chromatids. End joining is initiated by ATP-dependent DNA helicase 2 (XRCC6 encodes Ku70) and Ku80 heterodimer binding to the broken terminus. Ku70-Ku80 then recruits the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) to the DNA ends. The DNA-PKcs uses ligase IV to mediate ligation; this leads to end processing that seals the duplex DNA binding site (9) . Recent studies report that activating NHEJ repair through the interaction of the DNA-PKcs with its partners induces chemoresistance in cancer cells (10) and that inhibiting it induces chemosensitization (11) . Thus, targeting the NHEJ pathway is an innovative cancer therapy strategy (12) (13) (14) .
The primary purpose of chemotherapy is to inhibit the division and proliferation of cancer cells; however, it is usually cytotoxic (15) . Anticancer drugs damage DNA and topoisomerase I or II, which causes DNA DSB and single-strand breaks (5, 16) . However, chemoresistance and disease progression are common in clinical practice (17) . Several mechanisms have been proposed to explain this: ABC transporter, antiapoptosis, and cancer stem cells (18) (19) (20) . In addition, tumor hypoxia is a driving force of genetic instability and is pivotal in cancer development and chemoresistance (1, (21) (22) (23) . Hypoxic cancer cells usually exhibit dysregulated DNA repair (24) (25) (26) , but data conflict about the functional status of the NHEJ repair pathway under hypoxia (27) (28) (29) . The molecular basis of DNA repair-mediated chemoresistance under hypoxia thus deserves further investigation.
RON (Recepteur d'Origine Nantais; also known as macrophage-stimulating protein receptor (MST1R)], belongs to the cMet receptor tyrosine kinase (RTK) superfamily (30) . Membranous RON activates downstream signaling pathways, which causes the metastatic progression of epithelial cancer (31) (32) (33) . Evidence of the nuclear translocation of RTKs in the transactivation of target genes is increasing (34) (35) (36) . EGFR is the most well-known example of the nuclear import of RTK. Nuclear EGFR stimulates tumorigenesis, partly because it activates NHEJ repair by interacting with Ku70 and DNA-PKcs in response to ionizing radiation and cisplatin treatments (37) (38) (39) (40) . We recently reported (41, 42) that nuclear RON provided a survival advantage for cancer cells in response to serum starvation and hypoxia (41, 42) .
We investigated the biologic significance of nuclear RON and its underlying mechanisms in response to hypoxia. Nuclear RONassociated proteins were identified by co-immunoprecipitation (co-IP) of nuclear extract and fractionation with high-performance liquid chromatography/tandem mass spectrometry (HPLC/MS-MS), which indicates that both Ku70 and the DNAPKcs catalytic subunit (DNA-PKcs), important for NHEJ DNA repair, are associated with nuclear RON under hypoxia (Supplementary Table S1 ). Chemotherapy-induced DSBs also activate the interaction of nuclear RON with DNA-PK/Ku70. The results suggest that DNA NHEJ repair activated by nuclear RON may provide a survival advantage for hypoxic cancer cells in response to DSB. Thus, inhibiting RON is indispensable for increasing the chemosensitivity of RON-overexpressing tumors.
Materials and Methods

Cell lines, oxygen deprivation, and anticancer drugs
Both the J82 human urinary bladder cancer cell line and HEK293 human embryonic kidney cells were purchased from ATCC in 2005, and the TSGH8301 grade 2 human bladder carcinoma cell line from the Bioresource Collection and Research Center in October 2009. Cell lines were authenticated using short tandem repeat (STR)-PCR profiling in February 2014, as previously described (42) . The RON-knockdown or deletion mutants of RON-stable cell lines were established from TSGH8031 and J82 cells, respectively, as previously described (42) . All cell lines were maintained in DMEM (Invitrogen) supplemented with 10% FBS (Hyclone), and antibiotic/antimycotic solution (Caisson Laboratories: GeneDirex). Cells were cultured at 37 C in a humidified atmosphere of 5% CO 2 . The day before the experiments, cells (7 Â 10 5 ) were seeded in 6-mm dishes overnight. The medium was refreshed the next day and placed in a hypoxia chamber (NexBiOxy) filled with 95% N 2 and 5% CO 2 to control O 2 at 1% for different periods. The hypoxic equipment was plated within a 37 C humidified incubator (Forma). The anticancer drugs chosen for the experiments were as follows: etoposide (Sigma-Aldrich), mitomycin C (MDBio), and doxorubicin and epirubicin (Pfizer).
Immunohistochemical staining, immunofluorescent staining, and confocal microscopy
The immunohistochemical staining, immunofluorescent staining, and confocal microscopy were conducted as described previously (42) . The primary antibodies for human RON (1:200 dilution; C-20, Santa Cruz Biotechnology), HIF-1a (1:400 dilution; BD Transduction Laboratories), and gH2AX (1:400 dilution; ser139, Cell Signaling Technology) were incubated overnight at 4 C. The cells were then incubated with either Alexa Fluor 488 (mouse)-or Alexa Fluor 594 (rabbit)-conjugated secondary antibody (Invitrogen) at room temperature for 1 hour. DAPI was used for nuclear staining. The image analysis was done using a confocal microscope (FV1000; Olympus) with a 60Â/1.4 NA oil objective lens (PLAPO; Leica). The images were adjusted using graphics software (Photoshop CS5; Adobe). The intensity of gH2AX foci was quantified using ImageJ (http://imagej.nih.gov/ij/). IHC of the primary tumor was done using the primary antibodies for RON b (Santa Cruz Biotechnology), Ku70 (GeneTex), or CD31 (Dako).
Cell lysis, cellular fractionation, co-IP, and Western blotting Cell lysis, subcellular fractionation, and co-IP experiments were done as described previously (42) . In brief, cells were washed and lysed with RIPA buffer. Total protein was harvested after the cells had been centrifuged at 19,060 Â g for 15 minutes at 4 C, and the supernatant was kept for a protein concentration determination assay (Bio-Rad). For cellular fractionation, cells were washed with PBS and centrifuged. The resulting cell pellet was resuspended in Buffer A, and then crushed to release the nuclei using a Dounce homogenizer. The supernatant contained the non-nuclear fraction after it had been centrifuged for 5 minutes at 300 Â g. The pellet was washed twice with Buffer A and then centrifuged for 5 minutes at 300 Â g. The pellet was then resuspended in S1 buffer (3 mL) and layered over a 3-mL cushion of S3 after it had been centrifuged at 2,800 Â g for 10 minutes. Next, it was lysed with RIPA buffer and then centrifuged and the supernatant was collected as the nuclear fraction.
For IP, cells subjected to hypoxia for different durations were harvested and total lysates or fractionations from the non-nuclear and nuclear groups were incubated with the human RON antibody (Santa Cruz Biotechnology) overnight. For domain mapping, anti-FLAG (Sigma-Aldrich) or anti-HA antibody (Covance) was used for IP. After it had been incubated overnight, protein-G or protein-A sepharose CL-4B (Invitrogen) was incubated for another 4 hours, subjected to repeated pull-down assays, washed five times in PBS, and RON-associated protein complexes were separated using SDS-PAGE. Finally, the membrane was immunoblotted using antibody against human Ku70 (GeneTex) or RON.
For Western blotting, equal amounts of the samples were loaded and separated using 7.5%-10% SDS-PAGE and transferred to a 0.45-mm polyvinylidene difluoride membrane (Millipore). After it had been blocked with 5% nonfat milk in TBS-T (0.1% Tween-20), the membrane was hybridized with primary antibody and then secondary antibody. The membrane was then exposed to radiographic film and developed using chemiluminescent HRP substrate (Millipore). The primary antibodies used in this study included antibody against human Ku70 and RONb (Santa Cruz Biotechnology), DNA-PKcs and phospho-DNA-PKcs (ser2056; GeneTex), p-ATM (S-1981; Abcam), ATM, gH2AX, and H2AX (Epitomics), HIF-1a (BD Transduction Laboratories), and b-actin (Millipore). The details of the trypsin digestion and HPLC/MS-MS identification are provided in the Supplementary Materials and Methods.
Plasmid end-joining assay
A plasmid end-joining assay was conducted using pGL3 control vector (Promega), as described previously (43) . The pGL3 control vector was completely linearized using Hind III restriction endonucleases and confirmed using agarose gel electrophoresis. The linearized DNA was extracted with phenol and chloroform, precipitated with ethanol, and dissolved in sterilized water. The linearized DNA was then transfected into cells, harvested, and assayed for luciferase activity using a Dual Luciferase Reporter Assay System (Promega).
MTT cell proliferation assay
An MTT cell proliferation assay was done, as previously described (42) . In brief, cells were seeded overnight in 96-well plates in triplicate at l,000 cells/well for TSGH8301 cells or 200 cells/well for J82-stable cells. After they had been incubated overnight, the cells were treated with anticancer drugs for 24 hours and then transferred to standard DMEM for an additional 24 hours under normoxia or hypoxia. After they had been incubated at 37 C for the indicated period, MTT solution (0.25 mg/ mL) was added to the medium for 4 hours. Formazan crystals were then dissolved in DMSO and measured at 570 nm using an ELISA reader. The untreated TSGH8031/Vector or J82/Vector-stable cell line was used as a control and set as 100%.
Results
Interaction partners of nuclear RON identified using co-IP-HPLC/MS-MS
We recently showed (42) that nuclear translocation of RON provided a survival advantage for cancer cells in response to hypoxia. To clarify the mechanisms of this effect, the nuclear extract of hypoxic TSGH8301 cells was co-immunoprecipitated with RON antibody, and then analyzed using HPLC/MS-MS. By using this platform, both Ku70 and DNA-PKcs, key proteins involved in NHEJ repair for DNA DSBs, were identified (Supplementary Tables S1 and S2) , which prompted us to investigate how nuclear RON affects NHEJ repair under hypoxia.
DNA DSB and NHEJ repair activation under hypoxia
Because the regulation of DNA damage and repair under hypoxia remains unclear, we first examined, in TSGH8301 cells, in relation to normoxia or hypoxia, phosphorylation on serine-139 of gH2AX, a well-known biomarker of DNA DSBs. Confocal microscopy revealed a time-dependent increase of gH2AX foci in the nuclei under hypoxia than under normoxia (Fig. 1A, top) . The observation was confirmed by quantification of gH2AX foci using fluorescent microscopy (Fig. 1A, bottom) . gH2AX foci activated by hypoxia accumulated in the nuclei of TSGH8301 cells.
We then analyzed the expression of the DNA repair sensor proteins DNA-PKcs and ATM during hypoxia. Western blotting demonstrated a time-dependent increase of phospho-ATM and phospho-DNA-PKcs after hypoxia (Fig. 1B and Supplementary  Fig. S1 ). The gH2AX and HIF-1a were used as markers for DSBs and hypoxia, respectively. Interestingly, although NHEJ and HR repair pathways were activated under hypoxia, the level of Ku70 expression remained unchanged (Fig. 1B) . To examine DNA DSB repair efficiency in response to hypoxic stress, we used a plasmid end-joining assay to assess NHEJ repair activity. TSGH8301 target cells were transiently transfected with Hind III-linearized pGL3-control vector and control cells with nonlinearized vector, and then they were incubated under normoxia or hypoxia for 24 or 48 hours. The luciferase activity showed a higher repair percentage in TSGH8301 cells after hypoxia treatment than after normoxia treatment for 24 or 48 hours ( Fig. 1C ; P < 0.0001).
Hypoxia-activated end-joining activity was regulated by RON through DNA-PKcs
We previously showed that membranous expression of RON can be translocated into the nuclei of cancer cells in response to serum starvation or hypoxia (41, 42) . To explore the significance of RON for DSB repair, we used an end-joining assay to evaluate TSGH8301-stable RON knockdown cells and the control vector TSGH8301 cell line (TSGH8301/kdRON and TSGH8301/vector) after hypoxia treatment for 24 and 48 hours (Fig. 2A) . The repair activity was significantly (P < 0.01) suppressed in TSGH8301/ kdRON cells, and phosphorylated DNA-PKcs (phospho-Ser-2056) expression was lower in TSGH8301/kdRON cells than in control vector TSGH8301 cells after hypoxia for 6 and 24 hours (Fig. 2B) .
The histone H2AX protein can be phosphorylated (gH2AX) by ATM and DNA-PKcs (44, 45) . We thus examined whether gH2AX was regulated by DNA-PKcs in hypoxic TSGH8301 cells. Phospho-DNA-PKcs was dose dependently suppressed after 24 hours of hypoxia in cells treated with DNA-PKcs inhibitor (NU7026; Fig.  2C ). gH2AX foci expression was also significantly inhibited in cells treated with NU7026 after hypoxia for 6 and 24 hours (Fig. 2D) . This result implies that g-H2AX phosphorylation under hypoxia is due to DNA-PK, as opposed to replication fork collapse.
Interaction of nuclear RON with DNA-PK/Ku70 complex
To verify the association of nuclear RON with Ku70 and DNAPKcs, we used co-IP to evaluate the total lysate of TSGH8031 cells after hypoxia for different durations. RON was immunoprecipitated with Ku70 and DNA-PK after hypoxia for 3, 6, 12, and 24 hours (Fig. 3A) . Subcellular localization was confirmed in immunoprecipitation experiments in which both cytosolic and nuclear fractions were incubated with RON antibody. Interaction of RON with the Ku70/DNA-PK complex occurred in the nuclear fraction of TSGH8301 cells after hypoxia for 3, 6, 12, and 24 hours (Fig. 3B  and C) . The results were verified using confocal microscopy, which showed colocalization of nuclear RON with Ku70 or DNA-PK after hypoxia for 3, 6, 12, and 24 hours (Fig. 3D and E ).
An in vivo binding assay was then used to identify the functional domain responsible for the interaction of nuclear RON with the Ku70/DNA-PK complex under hypoxia. Because DNA-PKcs is very large (450 kDa) and difficult to prepare as a construct, Ku70 was chosen as the target protein. HEK293 cells were cotransfected with different functional domain deletion mutants of Flag-tag RON and full-length Ku70 with an HA-tag. Co-IP experiments used either Flag-tag or HA-tag antibody for Western blotting (Fig.  4A and B) . etoposide, doxorubicin, epirubicin, and mitomycin C, which is a crosslinking agent, but NHEJ is not involved in interstrand crosslink repair (46) . Thus, mitomycin C was used as a DSB control. Confocal microscopy showed an increase of gH2AX foci and nuclear RON in TSGH8301 cells after they had been treated with doxorubicin, epirubicin, and mitomycin C, respectively, for 24 hours (Supplementary Fig. S2 ). Both phospho-ATM (p-ATM) and phospho-DNA-PKcs (p-DNA-PKcs) were significantly upregulated in TSGH8301 cells after they had been treated with doxorubicin or epirubicin for 24 hours (Fig. 4C) . However, p-ATM was significantly upregulated and p-DNA-PKcs was weakly upregulated after the cells had been treated with mitomycin C. Western blotting of co-IP with RON antibody confirmed the interaction of nuclear RON with Ku70 and DNA-PKcs after the cells had been treated with anticancer drugs (Fig. 4D ).
Biologic implications of nuclear RON in response to treatment with anticancer drugs under hypoxia
To examine the clinical implications of RON for cancer cell survival, TSGH8031/vector and TSGH8301/kdRON-stable cell lines were treated with anticancer drugs and then subjected to normoxia or hypoxia. The experimental design is shown in the top panel of Fig. 5 . Cell count was measured using an MTT assay after each treatment. Confocal microscopy was used to examine the subcellular distribution. Cell count was significantly lower in TSGH8301/kdRON-stable cells, but not in TSGH8031/vector DSBs and DNA NHEJ repair activated under hypoxia. A, confocal microscopy (top) shows a time-dependent increase of gH2AX foci (DSB marker) in TSGH8301 cells under hypoxia. Bottom, quantification of gH2AX foci at different time periods. Mitomycin C (MMC) was used as a control. B, DNA repair activation under hypoxia was examined using Western blotting. Equal amounts of protein (50 mg) were loaded for each sample. b-Actin was used as a loading control and HIF-1a was used as a hypoxic control. C, NHEJ repair capability was assayed using an end-joining assay. Hind III-linearized or circular pGL3 with pRL-TK (Renilla) was cotransfected into TSGH8031 cells and incubated under normoxia or hypoxia for 0, 24, or 48 hours. The luciferase activity was normalized for equal transfection efficiency using the Renilla activity. The end-joining efficiency (%) was calculated by dividing the relative luciferase activity of the Hind III-linearized pGL3-transfected cells by the relative luciferase activity of the circular pGL3-control vector-transfected cells. Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001 (t test).
cells, within the first 24 hours after they had been exposed to doxorubicin, epirubicin, or mitomycin C (Fig. 5A) ; however, there was no significant difference after the cells had been exposed to etoposide and cisplatin ( Supplementary Fig. S3 ).
To clarify the effect of RON on DNA repair under hypoxia, TSGH8301/kdRON and TSGH8301/vector cells were incubated for an additional 24 hours under normoxia (Fig. 5B) or hypoxia ( Fig. 5C ) with anticancer drugs in fresh normal medium, after which there was no significant difference in cell survival under normoxia. The most interesting finding was the lower level of cell survival in TSGH8301/kdRON-stable cells under hypoxia compared with TSGH8301/vector stable cells in the presence of doxorubicin or epirubicin (Fig. 5C ). Confocal microscopy confirmed that nuclear RON colocalized with Ku70 in hypoxic TSGH8301/vector-stable cells in the presence of doxorubicin or epirubicin ( Supplementary Fig. S4A and S4B ).
Resistance of RON functional mutants to epirubicin treatment
We recently reported that both the transmembrane domain deletion mutant and full-length RON accumulate in the nuclei under hypoxia, but that the tyrosine kinase deletion mutant does not (42) . Epirubicin is one of the most frequently used drugs for intravesical chemotherapy for human bladder cancer. We used the J82 cell line, which has a lower level of RON expression than TSGH8031 cells, to establish a stable clone (42) . To examine the effect of nuclear RON on cell survival, J82-stable cell lines that overexpressed vector control, RONDTM, RONDTyrK, and RONFLstable cell lines were analyzed in the presence of epirubicin under normoxia and hypoxia. The J82 cells that overexpressed RONFL and RONDTM had a higher survival rate than those that overexpressed vector control or RONDTyrK 24 hours after treatment with epirubicin ( Fig. 6A ; P < 0.0001). The J82 cells that overexpressed RONDTM had a higher survival rate than those that and RON-knockdown (TSGH8031/kdRON) stable cell lines were cotransfected using Hind III-linearizer or circular pGL3-control vector with pRL-TK and incubated under normoxia or hypoxia for 24 and 48 hours. TSGH8301/kdVector-stable cells transfected with circular pGL3-control vector were set as 100%. B, expression of phospho (p)-DNA-PKcs (phosphoserine-2056) in TSGH8031/kdRON-stable cells was examined after hypoxia for 0, 6, and 24 hours. C, after hypoxia for 24 hours, the cells showed a dose-dependent inhibitory effect of NU7026 on p-DNA-PKcs (serine 2056). D, the effect of NU7026 (20 mmol/L) on gH2AX and DNA-PKcs expression under hypoxia was examined in TSGH8301 cells. Cells were fixed and treated with immunofluorescent staining. The images were captured using confocal microscopy. HIF-1a was used as the hypoxia control [ns, not significant; Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001 (two-way ANOVA)]. See previous figure legends for abbreviations.
overexpressed vector control and RONDTyrK within the two-dose range of epirubicin (0.56 and 1.125 mmol/L, P < 0.05; Fig. 6B ). The cell survival percentage was significantly higher in RONFL-RONDTM-overexpressing J82-stable cells vector control-or RONDTyrK-overexpressing J82-stable cells when they were incubated for 24 hours under hypoxia ( Fig. 6C ; P < 0.0001). Interaction of nuclear RON with Ku70/DNA-PKcs under hypoxia. A, total lysate was harvested from TSGH8301 cells after hypoxia for 0, 3, 6, 12, or 24 hours. After the cells had been immunoprecipitated using RON antibody, their interaction with Ku70 and DNA-PKcs was examined using the indicated antibodies. B and C, hypoxic cells were separated into nonnuclear (Non-Nu) and nuclear (Nu) fractions. Subcellular fractions were co-immunoprecipitated with RON antibody and probed using the indicated antibodies. b-Tubulin and lamin B1 were used as cytosolic and nuclear markers, respectively. The input samples were loaded with 5% of immunoprecipitation lysate. Hypoxic TSGH8301 cell lysate was used as a positive control (PC). D and E, images captured using confocal microscopy of TSGH8301 cells after they had been incubated under hypoxia for different durations. Red indicates the localization of RON and green indicates DNA-PKcs (D) and Ku70 (E). Hypoxic cells were fixed using paraformaldehyde (D) and methanol/acetone (E). See previous figure legends for abbreviations. 
Clinical implications in human bladder cancer
Our recent study demonstrated that primary bladder cancer cells remote from the basement membrane (>70 mm) have a significantly higher incidence of nuclear RON expression (42) . In the current study, immunohistochemical staining of primary bladder cancer confirmed our previous finding of a significantly higher incidence of nuclear RON expression in primary bladder cancer cells remote from the basement membrane (>70 mm), nuclear expression of Ku70, and RON in the nuclei of cancer cells remote from the basement membrane ( Fig. 6D-F; ref. 42 ).
Discussion
We found that hypoxic stress time dependently activated DSB and NHEJ DNA repair, as evidenced by the increase of gH2AX foci, upregulation of DNA repair-related proteins (p-ATM and p-DNA-PKcs), and activation of end-joining activity. In addition, both Ku70 and DNA-PKcs are associated with nuclear RON in vitro and in vivo in conjunction with hypoxia-induced DSBs. Because membranous RON receptor is transported to the nucleus of cancer cells during hypoxia (42) , nuclear RON might activate NHEJ DNA repair for DSB using the mechanism of DNA-PKcs (Fig. 6G) . Our findings are in sharp contrast to those of Chan and Bristow (24) , who showed that Ku70 was downregulated under hypoxia, which, in turn, led to a decrease in NHEJ repair (24) .
With the support of domain mapping, we showed that the tyrosine kinase domain of RON is important for interacting with Ku70, a result corresponding to its interaction with HIF-1a in the nuclei of cancer cells under hypoxia (42) . A recent study (47) showed that DNA-PK was important for regulating HIF-1 stability and its target gene, GLUT1, under hypoxia (47) . Taken together, these findings suggest that the tyrosine kinase domain of RON not only activates the intracellular signaling pathway, but also interacts with other nuclear proteins, HIF-1a, Ku70, and DNA-PKcs, when cancer cells are exposed to hypoxiainduced stress.
An intriguing finding of the current study is the nuclear translocation of RON and its interaction with Ku70/DNAPKcs in the presence of doxorubicin or epirubicin under hypoxia in vitro. Like hypoxic stress, treatment with these DNA-damaging drugs also activates the expression of p-ATM and p-DNA-PKcs. We found that anticancer drug-induced DNA DSBs activated RON nuclear translocation and NHEJ DNA repair by interacting with the Ku70/DNA-PKcs complex. We also showed that RON knockdown sensitized cancer cells to doxorubicin and epirubicin. In contrast, experiments using functional deletion mutants of RON in J82-stable cell lines provided additional support of the survival advantage of nuclear RON for cancer cells under hypoxia. Because nuclear EGFR-induced activation of NHEJ repair leads to cisplatin resistance (38, 40) , our data suggest that DSB-inducing anticancer drugs are not recommended for treating patients with RON-overexpressing cancer.
DSBs are a common lethal type of DNA damage induced by ionizing radiation and chemotherapeutic drugs, and thus the capability of cancer cells to efficiently repair DSBs significantly influences the outcome of chemotherapy. Hsu and colleagues (40) reported that both cisplatin resistance and DNA repair are dependent upon the nuclear translocation of EGFR, and Friedmann and colleagues (48) reported that gefitinib's inhibition of EGFR suppresses DNA repair after cisplatin treatment. Kriegs and colleagues (49) also reported reduced DSB repair after treatment with EGFR-specific antibody (cetuximab) or tyrosine kinase inhibitor (erlotinib). Taking these findings together with those of the current study provides support for using tyrosine kinase inhibitor or mAbs to target RON kinase as an anticancer strategy.
However, DNA interstrand crosslinks are also genotoxic (50) . A recent investigation of Fanconi anemia (46) supports the importance of interstrand crosslink repair in carcinogenesis. Whether DNA interstrand crosslink repair is affected by nuclear RON merits additional investigation.
In summary, we showed that hypoxia activated DSBs and triggered NHEJ DNA repair. DSB damage induced by anticancer drugs under hypoxia initiates RON nuclear translocation. After interaction with the Ku70/DNA-PKcs complex, nuclear RON- Figure 6 . Survival of J82-stable cell lines under hypoxia in the presence of anticancer drugs, and Ku70 and RON expression in primary bladder cancer tissue. An MTT assay was used on J82-stable cell lines overexpressing vector control (J82/Vector), transmembrane domain deletion (J82/RONDTM), tyrosine kinase domain deletion (J82/RONDTyrK), and full-length RON (J82/RONFL) to examine cell survival (A) 24 hours after they had been treated with, but not incubated with, epirubicin, and then 24 hours after they had been treated with and then incubated with epirubicin for 24 hours under normoxia (B) and under hypoxia (C). D-F, IHC was used to examine the topographic distribution of biomarkers and their relationship with blood vessels in frozen human bladder cancer tissue. The results are shown for Ku70 (D), CD31 (E, endothelial marker), and RON (F) stainings. Red arrowheads, the basement membrane; Ã , the region where the high-power image (inset) was taken. G, a hypothetical model of RON nuclear translocation in response to cellular stress. A conventional RON-mediated signaling cascade can modulate gene expression (gray arrows on right side). Hypoxic stress triggered RON nuclear translocation and interaction with HIF-1a in the transactivation of c-JUN promoter activity (gray arrow on left side). Nuclear RON also interacted with Ku70/DNA-PKcs complex to activate NHEJ DNA repair in response to hypoxia and DSB-inducing agents (black arrow). Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001 (two-way ANOVA). See previous figure legends for abbreviations.
activated NHEJ repair confers chemoresistance to DSB-inducing drugs. Thus, tyrosine kinase inhibitor or mAbs that target kinase should be considered when treating patients with RON-overexpressing tumors. In addition, DSB-inducing anticancer drugs are not recommended in the treatment planning for these patients.
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